Salute e Benessere

Council of ASEAN Chief Justices reflect milestones and achievements over the…

The CACJ also endorsed codes and standards such as the Model Principles of Judicial Conduct, and acknowledged the International Framework for Court Excellence, a self-assessment tool that the ASEAN Judiciaries can voluntarily adopt to identify areas of strength and areas for improvement. These have strengthened the Rule of Law in the ASEAN region by facilitating cooperation and capacity building. The CACJ also endorsed codes and standards such as theModel Principles of Judicial Conduct, and...

Wingderm® Has Unveiled the Latest Research of Mesoskin for Mesotherapy Treatment…

Multiple clinical trial results show that compared to transdermal introduction methods such as nanocrystals, derma rollers, and water injections, EPM technology results in less skin damage, higher permeability and more even subcutaneous hyaluronic acid distribution in the delivery of 150KDa hyaluronic acid, it performs well in both skin experience and treatment efficacy. This research achievement once again reaffirmed the comprehensive advantages of Mesoskin for Mesotherapy Treatment in…

Pharmaceutical Suppositories Market to Reach $2.8 Billion, Globally, by 2032 at…

Request Sample of the Report on Pharmaceutical Suppositories Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/12715 Request Sample of the Report on Pharmaceutical Suppositories Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/12715 Pharmaceutical suppositories are solid or semi-solid medication forms designed for insertion into various body cavities, primarily the rectum, vagina, or urethra, with the purpose of administering drugs...

The Changing Market Landscape of Benign Soft Tissue Sarcomas: Tenosynovial Giant…

DelveInsight has recently released a series of epidemiology-based market reports focusing on benign soft tissue sarcomas including Tenosynovial Giant Cell Tumors (TGCTs), Perivascular Epithelioid Cell Neoplasm (PEComa), Neurofibroma, and Vestibular Schwannoma. These reports include a comprehensive understanding of current treatment practices, historical and forecasted patient pool, emerging drugs, market share of individual therapies, and historical and forecasted market size from 2019 to 2032…

TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy”…

Lyon (France) et Cambridge (MA, US), October 23, 2023, at 10:05 pm CEST – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for resistant bacterial infections,today announced that TP ICAP Midcap, a brokerage firm and investment bank specializing in small and mid-caps, has initiated coverage of its shares. In its initiation study entitled “ Ambition de leadership mondial de la phagothérapie -Ambition for global leadership in...

Innocan Pharma reports a groundbreaking discovery regarding its LPD platform and…

A Milestone in Drug Approval Process A Milestone in Drug Approval Process This groundbreaking discovery, is not unique to our LPT-CBD and can be implemented on these animals using other Cannabidiol (CBD) delivery methods", said Iris Bincovich, CEO of Innocan Pharma. This is an important piece of the puzzle, which expected to not only facilitate our application for FDA approval, but also open new horizons for global medical research with CBD,". "We are committed to using this…

LifeSpan Vision Ventures Invests in Matter Bio

Matter Bio expects to initiate clinical trials for one of its programs in the next 12 months, as well as scale-up an already revenue generating program in the single molecule mutation sequencing space. Matter Bio expects to initiate clinical trials for one of its programs in the next 12 months, as well as scale-up an already revenue generating program in the single molecule mutation sequencing space. Dr.Jordan B. Burton, Scientific Analyst at LifeSpan Vision Ventures, stated: "Our...

Jan Gurander proposed as new Chairman of Essity

Jan Gurander is currently a member of the Board of Directors of Skanska and Essity. Jan Gurander is currently a member of the Board of Directors of Skanska and Essity. The Nomination Committee of Essity Aktiebolag (publ) comprises representatives of four of the company's largest shareholders and the Chairman of the Board, Pär Boman. The members representing the largest shareholders areHelena Stjernholm(AB Industrivärden),Amy Wilson(Norges Bank Investment Management),Anders...

Monthly information related to total number of voting rights and shares…

Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2023.Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – FranceListing markets:Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: PHXM) &Nasdaq Global Select Market in the United-States (Symbol: PHXM) Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut...

VIRBAC: revenue growth at the end of September at +2.8% at constant exchange…

KEY FIGURES Revenue Nine months, 2023 €925.3 millionGrowth at constant exchange ratesand scope 1 +2.8%of which companion animals +1.1%farm animals +5.0%Growth at constantexchange rates +2.8% Overallchange +0.4% 1 growth at constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, by calculating the indicator for the...

BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy…

BNT211 combines two innovative approaches in one regimen with first-in-class potential: an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding CAR-T cell amplifying RNA vaccine (“CARVac”)Data presented at ESMO Congress 2023 demonstrates that the application of CARVac increases the persistence of the adoptively transferred autologous CAR-T cellsBNT211 continues to show encouraging antitumor activity in patients with CLDN6-positive...

LBB Specialties Announces Principal Partnership with Viscofan

Viscofan DE is the center of excellence for collagen products within the Viscofan group. Viscofan applies proprietary technologies and standardized extraction methods to process collagen from bovine skin for the development and industrial-scale production of novel collagen ingredients and biometrics. Viscofan DE is the center of excellence for collagen products within the Viscofan group. Viscofan applies proprietary technologies and standardized extraction methods to process collagen from...

Novartis Pluvicto™ shows clinically meaningful and highly statistically…

Phase III PSMAfore trial with Pluvicto™met its primary endpoint of radiographic progression-free survival (rPFS) with a HR of 0.41 1 ; Pluvicto more than doubled median rPFS to 12.0 months per updated analysis* 1 Pluvicto also showed improved quality of life compared to daily oral ARPI, along with improvements in other clinically meaningful efficacy endpoints 1 Overall survival (OS) data interpretation at second interim analysis was confounded by 84% crossover 1 ;...

XINGIMAGING and MITRO BIOTECH CO., LTD. MERGE TO DELIVER FULL-SERVICE CRO…

"We are very excited to welcome XingImaging to the Mitro team. XingImaging's experience and know-how are extraordinarily complementary to Mitro. Expansion of our combined offerings provides our pharmaceutical industry and biotech partners with a continuum of research services utilizing start-of-the-art technology of molecular imaging and radio-pharmaceutical in-vivo targeting," said Grant Luo, Chairman of Mitro. Furthermore, "XingImaging's clinical imaging network in China, and…

In Vitro Diagnostics Market to Reach $138.4 Billion, Globally, by 2032 at 4.1%…

Request Sample of the Report on In Vitro Diagnostics Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/336 In Vitro Diagnostic is a medical procedure that involves the examination, diagnosis, and monitoring of a sample taken from the human body, such as a blood sample, urine sample, or tissue sample, in a laboratory environment. The term "in vitro" is derived from the Greek word "in vitro", which translates to "in glass". IVD covers a broad…

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the…

One of the more promising developments in treatment is pelareorep, the flagship drug candidate of Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), which was given a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer by the FDA in late 2022. The FDA's decision came almost immediately after an update on ONCY'sGOBLET study, which delivered amazing results, including a 69% objective response rate (ORR) in the first group of patients tested and one even having a rare…

Certa Therapeutics' FT011 Granted US FDA Orphan Drug Designation for the…

"We are very pleased that the FDA has granted Orphan Drug Designation to FT011 which we believe highlights the urgent need for innovation and new therapeutic options for scleroderma patients" said Professor Darren Kelly, Certa Therapeutics CEO and founder. "This designation represents an important milestone in the development of FT011, which has the potential to establish first-in-class clinical benefits by precisely targeting the root cause of fibrosis and offer treatment across…

Resolutions of the Extraordinary General Meeting of BBS-Bioactive Bone…

BBS-Bioactive Bone Substitutes Plc, Company Announcement, 23 October 2023 at 4.30 pm (EET)Resolutions of the Extraordinary General Meeting of BBS-Bioactive Bone Substitutes Plc BBS-Bioactive Bone Substitutes Plc's Extraordinary General Meeting (EGM) was held at the company's premises in Oulu on Monday 23 October 2023 starting at 2.00 pm (EET).The Extraordinary General Meeting authorized the Board of Directors to decide in one or more instalments on share issues and on the issuance of...

The Committee to Restore Nymox Shareholder Value Sends Letter to Nymox…

CARSON CITY, Nev. and LONDON, Oct. 23, 2023 /PRNewswire/ -- The Committee to Restore Nymox Shareholder Value, Inc. ("CRNSV"), with a goal to recover shareholder value in Nymox Pharmaceutical Corporation (NYMX-F) (the "Company" or "Nymox"), today announced that it has delivered a letter to Nymox shareholders and issued a proxy statement and accompanying WHITE proxy card (the "Special Meeting Proxy Materials") in connection with the Special Meeting of…

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 23 October 2023– On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under…

Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal…

BMC Medicine continued, 'PAR1 overexpression was found to be closely associated with tumor progression and poor survival outcomes in PDAC. Rather than being specific to tumor cells, PAR1 is expressed by the surrounding stroma that consists of endothelial cells, fibroblasts, and macrophages. Activation of stromal cell-associated PAR1 expression in the TME leads to increased vascular permeability, ECM production, and cytokine secretion, thereby promoting tumorigenesis. In this study, we developed…

Aster Guardians Global Nursing Award 2024 is now open for entry worldwide, One…

Nurses can apply in one Primary and up to two Secondary areas of contribution, namely – Patient Care, Nursing Leadership, Nursing Education, Social or Community service and Research/ Innovation/ Entrepreneurship in Healthcare. The secondary areas of contribution can be optional. All applications received will follow a stringent review process led by an independent jury and an external advisory firm – Ernst & Young LLP (EY). The Grand Jury, consisting of an independent panel of...

Join Us at ESSO42 - Confidently navigating towards the target with GPSDetect™…

Sirius Medical will sponsor a luncheon satellite symposium on October 24 titled, "Pintuition GPSDetect Surgical Marker Navigation in breast conservative surgery, appreciating the technical benefits, the value to patient and to the healthcare system," chaired by Leena Chagla (St Helens and Knowsley, UK). She will be joined by Edward St. John (Portsmouth Hospitals NHS Trust, UK), Rosa Garcia (Hospital Clinic de Barcelona), Riccardo Giovanazzi (IRCCS S.Gerardo, IT) and Barry Rosen…

Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at…

— Pharmacokinetic Profile of ALKS 2680 Supports Once-Daily Dosing and Mimics the Natural Sleep/Wake Cycle — — Pharmacokinetic Profile of ALKS 2680 Supports Once-Daily Dosing and Mimics the Natural Sleep/Wake Cycle — — Consistent, Dose-Dependent Effects Enable Dose Selection for Evaluation in Planned Phase 2 Study — DUBLIN,Oct. 23, 2023/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced preliminary results, including initial proof-of-concept data, from a phase...

Altri Comunicati